Affimed Nv - Understand $afmd stock

$AFMD Market Cap: $57.1 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$2.684M

TTM

Gross Margin

Net Earnings

-$79.19M

TTM

Current Assets

$45.19M

Q2 2024

Current Liabilities

$16.67M

Q2 2024

Current Ratio

271.04%

Q2 2024

Total Assets

$53.17M

Q2 2024

Total Liabilities

$24.46M

Q2 2024

Book Value

$28.71M

Q2 2024

Cash

$10.76M

Q2 2024

P/E

-0.7211

Nov 13, 2024 EST

Free Cash Flow

-$87.76M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$8.275M	$41.35M	$40.37M	$28.36M	$21.39M	$23.74M	$2.010M	$6.310M	$7.560M	$3.380M	$5.090M	$1.170M
YoY Change	-79.99%	2.45%	42.33%	32.59%	-9.9%	1081.09%	-68.15%	-16.53%	123.67%	-33.6%	335.04%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$8.275M	$41.35M	$40.37M	$28.36M	$21.39M	$23.74M	$2.010M	$6.310M	$7.560M	$3.380M	$5.090M	$1.170M
Cost Of Revenue	$1.349M	$2.138M	$2.152M	$1.730M	$1.550M	$1.140M	$990.0K	$1.030M	$900.0K	$840.0K	$710.0K	$550.0K
Gross Profit	$6.926M	$39.22M	$38.21M	$26.63M	$19.84M	$22.60M	$1.020M	$5.290M	$6.660M	$2.540M	$4.380M	$620.0K
Gross Profit Margin	83.7%	94.83%	94.67%	93.9%	92.75%	95.2%	50.75%	83.84%	88.1%	75.15%	86.05%	52.99%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Selling, General & Admin	$26.03M	$33.25M	$25.52M	$16.10M	$12.25M	$11.31M	$8.880M	$9.080M	$8.450M	$3.900M	$8.450M	$3.820M
YoY Change	-21.71%	30.3%	58.5%	31.43%	8.31%	27.36%	-2.2%	7.46%	116.67%	-53.85%	121.2%
% of Gross Profit	375.86%	84.79%	66.78%	60.46%	61.74%	50.04%	870.59%	171.64%	126.88%	153.54%	192.92%	616.13%
Research & Development	$30.50M	$98.81M	$26.42M	$15.16M	$11.06M	$8.910M	$5.640M	$6.650M	$3.640M	$290.0K	$5.270M	$3.000M
YoY Change	-69.13%	273.96%	74.3%	37.07%	24.13%	57.98%	-15.19%	82.69%	1155.17%	-94.5%	75.67%
% of Gross Profit	440.36%	251.98%	69.15%	56.93%	55.75%	39.42%	552.94%	125.71%	54.65%	11.42%	120.32%	483.87%
Depreciation & Amortization	$1.749M	$2.899M	$1.334M	$1.120M	$910.0K	$400.0K	$350.0K	$370.0K	$340.0K	$440.0K	$430.0K	$410.0K
YoY Change	-39.67%	117.32%	19.11%	23.08%	127.5%	14.29%	-5.41%	8.82%	-22.73%	2.33%	4.88%
% of Gross Profit	25.25%	7.39%	3.49%	4.21%	4.59%	1.77%	34.31%	6.99%	5.11%	17.32%	9.82%	66.13%
Operating Expenses	$114.5M	$98.81M	$102.4M	$61.48M	$52.47M	$43.65M	$28.28M	$37.33M	$28.01M	$10.72M	$20.08M	$11.02M
YoY Change	15.9%	-3.47%	66.51%	17.17%	20.21%	54.35%	-24.24%	33.27%	161.29%	-46.61%	82.21%
Operating Profit	-$107.6M	-$59.60M	-$64.16M	-$34.85M	-$32.63M	-$21.05M	-$27.26M	-$32.04M	-$21.35M	-$8.180M	-$15.70M	-$10.40M
YoY Change	80.54%	-7.1%	84.09%	6.8%	55.01%	-22.78%	-14.92%	50.07%	161.0%	-47.9%	50.96%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Interest Expense	-$376.0K	$1.855M	$7.049M	-$6.470M	$190.0K	$1.330M	-$2.990M	$10.00K	$1.110M	$6.540M	-$5.920M	-$140.0K
YoY Change	-120.27%	-73.68%	-208.95%	-3505.26%	-85.71%	-144.48%	-30000.0%	-99.1%	-83.03%	-210.47%	4128.57%
% of Operating Profit
Other Income/Expense, Net	$2.044M	$361.0K	-$415.0K	-$50.00K	$70.00K	$250.0K	$10.00K	-$240.0K	$0.00	$1.220M	-$4.480M	-$3.780M
YoY Change	466.2%	-186.99%	730.0%	-171.43%	-72.0%	2400.0%	-104.17%		-100.0%	-127.23%	18.52%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Pretax Income	-$105.9M	-$86.00M	-$57.52M	-$41.37M	-$32.36M	-$19.48M	-$30.24M	-$32.27M	-$20.24M	-$430.0K	-$26.10M	-$14.32M
YoY Change	23.18%	49.51%	39.04%	27.84%	66.12%	-35.58%	-6.29%	59.44%	4606.98%	-98.35%	82.26%
Income Tax	$3.000K	$2.000K	$2.000K	$0.00	$0.00	$0.00	-$20.00K	-$60.00K	$0.00	-$170.0K	$0.00	-$10.00K
% Of Pretax Income
Net Earnings	-$105.9M	-$86.00M	-$57.52M	-$41.37M	-$32.37M	-$19.48M	-$30.22M	-$32.22M	-$20.24M	-$260.0K	-$26.10M	-$14.31M
YoY Change	23.18%	49.51%	39.05%	27.8%	66.17%	-35.54%	-6.21%	59.19%	7684.62%	-99.0%	82.39%
Net Earnings / Revenue	-1280.22%	-207.98%	-142.5%	-145.87%	-151.33%	-82.06%	-1503.48%	-510.62%	-267.72%	-7.69%	-512.77%	-1223.08%
Basic Earnings Per Share
Diluted Earnings Per Share	-$7.09	-$0.60	-$481.4K	-$495.6K	-$503.9K	-$321.9K	-$690.0K	-$970.2K	-$608.5K	-$10.84K	-$1.174M	-$643.7K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Cash & Short-Term Investments	$72.05M	$190.3M	$197.6M	$146.9M	$104.1M	$108.8M	$39.80M	$44.90M	$76.70M	$39.70M	$4.200M	$4.900M
YoY Change	-62.14%	-3.72%	34.53%	41.11%	-4.32%	173.37%	-11.36%	-41.46%	93.2%	845.24%	-14.29%
Cash & Equivalents	$38.53M	$190.3M	$197.6M	$146.9M	$95.20M	$94.80M	$39.80M	$35.40M	$76.70M	$39.70M	$4.200M	$4.900M
Short-Term Investments	$33.52M			$0.00	$8.900M	$14.00M	$0.00	$9.500M
Other Short-Term Assets	$6.351M	$2.459M	$3.534M	$1.300M	$0.00	$400.0K	$800.0K	$500.0K	$500.0K
YoY Change	158.28%	-30.42%	171.85%		-100.0%	-50.0%	60.0%	0.0%
Inventory	$463.0K	$628.0K	$421.0K	$200.0K	$300.0K	$300.0K	$200.0K	$200.0K	$200.0K	$200.0K	$100.0K	$100.0K
Prepaid Expenses
Receivables	$5.327M	$2.697M	$4.809M	$2.400M	$1.500M	$1.400M	$1.100M	$2.300M	$900.0K	$900.0K	$1.000M	$700.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$84.19M	$196.1M	$206.4M	$150.8M	$105.9M	$110.9M	$42.00M	$47.90M	$78.30M	$40.90M	$5.300M	$5.700M
YoY Change	-57.06%	-5.0%	36.87%	42.4%	-4.51%	164.05%	-12.32%	-38.83%	91.44%	671.7%	-7.02%
Property, Plant & Equipment	$12.94M	$4.384M	$4.786M	$3.200M	$3.100M	$1.400M	$1.100M	$800.0K	$900.0K	$1.000M	$1.000M	$1.200M
YoY Change	195.26%	-8.4%	49.56%	3.23%	121.43%	27.27%	37.5%	-11.11%	-10.0%	0.0%	-16.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$12.35M	$20.00M	$3.200M	$3.800M
YoY Change		-100.0%	-38.26%	525.0%	-15.79%
Other Assets										$0.00	$0.00	$0.00
YoY Change
Total Long-Term Assets	$12.97M	$4.442M	$18.74M	$24.90M	$6.500M	$5.300M	$1.200M	$800.0K	$1.000M	$1.000M	$1.200M	$1.500M
YoY Change	191.96%	-76.3%	-24.73%	283.08%	22.64%	341.67%	50.0%	-20.0%	0.0%	-16.67%	-20.0%
Total Assets	$97.16M	$200.5M	$225.1M	$175.7M	$112.4M	$116.2M	$43.20M	$48.70M	$79.30M	$41.90M	$6.500M	$7.200M
YoY Change
Accounts Payable	$18.92M	$19.08M	$18.86M	$11.40M	$10.70M	$9.400M	$4.200M	$5.300M	$4.400M	$3.800M	$3.900M	$2.000M
YoY Change	-0.84%	1.15%	65.44%	6.54%	13.83%	123.81%	-20.75%	20.45%	15.79%	-2.56%	95.0%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$3.100M	$1.000M	$1.500M	$0.00	$4.800M	$0.00
YoY Change						-100.0%	210.0%	-33.33%		-100.0%
Long-Term Debt Due	$6.372M	$6.326M	$1.263M	$600.0K	$2.600M	$3.100M
YoY Change	0.73%	400.87%	110.5%	-76.92%	-16.13%
Total Short-Term Liabilities	$25.91M	$34.65M	$64.55M	$67.00M	$35.20M	$36.80M	$7.500M	$6.400M	$8.900M	$6.200M	$14.90M	$2.100M
YoY Change	-25.23%	-46.32%	-3.66%	90.34%	-4.35%	390.67%	17.19%	-28.09%	43.55%	-58.39%	609.52%
Long-Term Debt	$12.98M	$11.86M	$17.43M	$700.0K	$600.0K	$1.700M	$4.100M	$3.600M	$3.100M	$3.900M	$77.90M	$73.50M
YoY Change	9.41%	-31.93%	2389.71%	16.67%	-64.71%	-58.54%	13.89%	16.13%	-20.51%	-94.99%	5.99%
Other Long-Term Liabilities	$464.0K	$1.083M	$7.209M	$36.00M	$38.00M	$37.50M				$0.00	$12.80M	$4.800M
YoY Change	-57.16%	-84.98%	-79.98%	-5.26%	1.33%					-100.0%	166.67%
Total Long-Term Liabilities	$13.44M	$12.95M	$24.64M	$36.70M	$38.60M	$39.20M	$4.100M	$3.600M	$3.100M	$3.900M	$90.70M	$78.30M
YoY Change	3.84%	-47.45%	-32.87%	-4.92%	-1.53%	856.1%	13.89%	16.13%	-20.51%	-95.7%	15.84%
Total Liabilities	$39.35M	$47.60M	$89.18M	$103.7M	$73.70M	$76.00M	$11.60M	$10.00M	$12.00M	$10.10M	$105.7M	$80.30M
YoY Change	-17.33%	-46.63%	-14.0%	40.71%	-3.03%	555.17%	16.0%	-16.67%	18.81%	-90.44%	31.63%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $57.103 Million

About Affimed NV

Affimed NV engages in the discovery and development of cancer immunotherapies. The company is headquartered in Mannheim, Baden-Wuerttemberg and currently employs 76 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Industry: Pharmaceutical Preparations Peers: Biontech SE CureVac NV InflaRx NV Immatics NV Mainz Biomed NV